Zevra Therapeutics, Inc. $ZVRA Holdings Cut by 683 Capital Management LLC

683 Capital Management LLC reduced its stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 8.2% in the second quarter, HoldingsChannel.com reports. The fund owned 1,125,000 shares of the company’s stock after selling 100,834 shares during the quarter. 683 Capital Management LLC’s holdings in Zevra Therapeutics were worth $9,911,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in ZVRA. Charles Schwab Investment Management Inc. lifted its holdings in shares of Zevra Therapeutics by 2.6% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 153,331 shares of the company’s stock worth $1,148,000 after purchasing an additional 3,827 shares during the last quarter. Wellington Management Group LLP acquired a new stake in Zevra Therapeutics in the first quarter worth $1,052,000. EntryPoint Capital LLC increased its position in Zevra Therapeutics by 53.8% in the first quarter. EntryPoint Capital LLC now owns 40,675 shares of the company’s stock worth $305,000 after buying an additional 14,225 shares during the period. Stonepine Capital Management LLC lifted its stake in Zevra Therapeutics by 8.8% in the first quarter. Stonepine Capital Management LLC now owns 650,000 shares of the company’s stock valued at $4,868,000 after buying an additional 52,300 shares during the last quarter. Finally, Velan Capital Investment Management LP boosted its holdings in shares of Zevra Therapeutics by 121.7% during the first quarter. Velan Capital Investment Management LP now owns 665,000 shares of the company’s stock valued at $4,981,000 after acquiring an additional 365,000 shares during the period. 35.03% of the stock is currently owned by institutional investors and hedge funds.

Zevra Therapeutics Stock Down 0.7%

Shares of ZVRA stock opened at $8.33 on Friday. Zevra Therapeutics, Inc. has a 1 year low of $6.19 and a 1 year high of $13.16. The stock has a market cap of $468.98 million, a PE ratio of 17.72 and a beta of 1.01. The business’s fifty day moving average is $9.67 and its 200-day moving average is $9.70. The company has a debt-to-equity ratio of 0.46, a quick ratio of 8.57 and a current ratio of 8.62.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.03. Zevra Therapeutics had a negative return on equity of 51.40% and a net margin of 41.93%.The business had revenue of $26.06 million during the quarter, compared to analyst estimates of $26.64 million. Equities analysts expect that Zevra Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Zevra Therapeutics news, CEO Neil F. Mcfarlane sold 19,500 shares of the company’s stock in a transaction dated Friday, October 10th. The shares were sold at an average price of $10.82, for a total value of $210,990.00. Following the completion of the sale, the chief executive officer directly owned 222,016 shares of the company’s stock, valued at approximately $2,402,213.12. This represents a 8.07% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 2.40% of the company’s stock.

Analysts Set New Price Targets

ZVRA has been the topic of a number of analyst reports. Wall Street Zen raised shares of Zevra Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Weiss Ratings restated a “sell (d+)” rating on shares of Zevra Therapeutics in a research report on Tuesday, October 14th. Zacks Research cut Zevra Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, August 18th. Canaccord Genuity Group reduced their price objective on Zevra Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a research report on Thursday, November 6th. Finally, Cantor Fitzgerald decreased their price objective on Zevra Therapeutics from $29.00 to $24.00 and set an “overweight” rating for the company in a report on Thursday, November 6th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.80.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.